FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2021156512> ?p ?o ?g. }

• W2021156512 endingPage "1185" @default.
• W2021156512 startingPage "1180" @default.
• W2021156512 abstract "SummaryIntroduction: Atrial fibrillation (AF) increases the risk of ischemic stroke 5‐fold and may not only be responsible for as many as 15% of all strokes that occur but also for larger and more disabling strokes than those attributable to other causes which increase the associated costs of care. Anticoagulation with warfarin in the target INR of 2.5 is a major clinical challenge in real‐life practice, given that the complex relationship between warfarin dosage and response is readily altered by a variety of factors such as concurrent medications, illnesses, genetic influences, and dietary/lifestyle changes. Consequently, INR values are out of the target range approximately half of the time in real‐life studies compared to clinical trial setting. Current anticoagulation therapies are less likely to be cost‐effective in routine clinical practice and need improvement. The aim of this review is to discuss the pharmacoeconomic consequences of this management strategy by analysing the optimal treatment option within specific age and risk groups, confirming current guidelines for a health economic perspective and considering the economic impact on health care policy. Methods: An electronic search of the Medline/PubMed database from 1966 to 2005 was performed to identify articles dealing with all pharmacoeconomic aspects of stroke prevention in atrial fibrillation. The following search terms were used: ‘atrial fibrillation’, ‘stroke’, ‘cost’, ‘warfarin’. Results: Treatment with warfarin is cost‐effective (versus aspirin or no therapy) in patients with AF at moderate‐to‐high risk of stroke. The cost‐effectiveness of anticoagulation therapy is driven by the achieved risk reduction rather than the potential benefits estimated from clinical trials. Failure to maintain optimal anticoagulation places patients at risk of complications, the management of which is a significant cost driver. Conclusion: Improvement could be achieved by optimising physicians and patient's knowledge driven through prevention campaigns by health care policy. Introduction: Atrial fibrillation (AF) increases the risk of ischemic stroke 5‐fold and may not only be responsible for as many as 15% of all strokes that occur but also for larger and more disabling strokes than those attributable to other causes which increase the associated costs of care. Anticoagulation with warfarin in the target INR of 2.5 is a major clinical challenge in real‐life practice, given that the complex relationship between warfarin dosage and response is readily altered by a variety of factors such as concurrent medications, illnesses, genetic influences, and dietary/lifestyle changes. Consequently, INR values are out of the target range approximately half of the time in real‐life studies compared to clinical trial setting. Current anticoagulation therapies are less likely to be cost‐effective in routine clinical practice and need improvement. The aim of this review is to discuss the pharmacoeconomic consequences of this management strategy by analysing the optimal treatment option within specific age and risk groups, confirming current guidelines for a health economic perspective and considering the economic impact on health care policy. Methods: An electronic search of the Medline/PubMed database from 1966 to 2005 was performed to identify articles dealing with all pharmacoeconomic aspects of stroke prevention in atrial fibrillation. The following search terms were used: ‘atrial fibrillation’, ‘stroke’, ‘cost’, ‘warfarin’. Results: Treatment with warfarin is cost‐effective (versus aspirin or no therapy) in patients with AF at moderate‐to‐high risk of stroke. The cost‐effectiveness of anticoagulation therapy is driven by the achieved risk reduction rather than the potential benefits estimated from clinical trials. Failure to maintain optimal anticoagulation places patients at risk of complications, the management of which is a significant cost driver. Conclusion: Improvement could be achieved by optimising physicians and patient's knowledge driven through prevention campaigns by health care policy." @default.
• W2021156512 created "2016-06-24" @default.
• W2021156512 creator A5082010319 @default.
• W2021156512 creator A5085045591 @default.
• W2021156512 date "2006-06-01" @default.
• W2021156512 modified "2023-09-29" @default.
• W2021156512 title "Pharmacoeconomics of anticoagulation therapy for stroke prevention in atrial fibrillation: a review" @default.
• W2021156512 cites W1972463800 @default.
• W2021156512 cites W1974615317 @default.
• W2021156512 cites W1998585195 @default.
• W2021156512 cites W2009519327 @default.
• W2021156512 cites W2015707574 @default.
• W2021156512 cites W2016621291 @default.
• W2021156512 cites W2027536394 @default.
• W2021156512 cites W2035728361 @default.
• W2021156512 cites W2040520826 @default.
• W2021156512 cites W2049165258 @default.
• W2021156512 cites W2057484890 @default.
• W2021156512 cites W2059231500 @default.
• W2021156512 cites W2060630424 @default.
• W2021156512 cites W2066267661 @default.
• W2021156512 cites W2066490209 @default.
• W2021156512 cites W2066891536 @default.
• W2021156512 cites W2067670780 @default.
• W2021156512 cites W2070460033 @default.
• W2021156512 cites W2089303565 @default.
• W2021156512 cites W2089534375 @default.
• W2021156512 cites W2091000151 @default.
• W2021156512 cites W2099144469 @default.
• W2021156512 cites W2109013673 @default.
• W2021156512 cites W2114775432 @default.
• W2021156512 cites W2119905314 @default.
• W2021156512 cites W2120088766 @default.
• W2021156512 cites W2127650467 @default.
• W2021156512 cites W2128128004 @default.
• W2021156512 cites W2150865594 @default.
• W2021156512 cites W2153196285 @default.
• W2021156512 cites W2158454439 @default.
• W2021156512 cites W2164327527 @default.
• W2021156512 cites W2169233115 @default.
• W2021156512 cites W2281337880 @default.
• W2021156512 cites W2465663631 @default.
• W2021156512 cites W2912412306 @default.
• W2021156512 cites W3023254611 @default.
• W2021156512 cites W4256234224 @default.
• W2021156512 doi "https://doi.org/10.1111/j.1538-7836.2006.01890.x" @default.
• W2021156512 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16706956" @default.
• W2021156512 hasPublicationYear "2006" @default.
• W2021156512 type Work @default.
• W2021156512 sameAs 2021156512 @default.
• W2021156512 citedByCount "30" @default.
• W2021156512 countsByYear W20211565122012 @default.
• W2021156512 countsByYear W20211565122013 @default.
• W2021156512 countsByYear W20211565122014 @default.
• W2021156512 countsByYear W20211565122015 @default.
• W2021156512 countsByYear W20211565122017 @default.
• W2021156512 countsByYear W20211565122023 @default.
• W2021156512 crossrefType "journal-article" @default.
• W2021156512 hasAuthorship W2021156512A5082010319 @default.
• W2021156512 hasAuthorship W2021156512A5085045591 @default.
• W2021156512 hasBestOaLocation W20211565121 @default.
• W2021156512 hasConcept C112930515 @default.
• W2021156512 hasConcept C126322002 @default.
• W2021156512 hasConcept C127413603 @default.
• W2021156512 hasConcept C160735492 @default.
• W2021156512 hasConcept C162324750 @default.
• W2021156512 hasConcept C164705383 @default.
• W2021156512 hasConcept C17744445 @default.
• W2021156512 hasConcept C177713679 @default.
• W2021156512 hasConcept C199539241 @default.
• W2021156512 hasConcept C2776301958 @default.
• W2021156512 hasConcept C2776738588 @default.
• W2021156512 hasConcept C2777628954 @default.
• W2021156512 hasConcept C2779161974 @default.
• W2021156512 hasConcept C2779473830 @default.
• W2021156512 hasConcept C2780645631 @default.
• W2021156512 hasConcept C3019080777 @default.
• W2021156512 hasConcept C50522688 @default.
• W2021156512 hasConcept C71924100 @default.
• W2021156512 hasConcept C78519656 @default.
• W2021156512 hasConceptScore W2021156512C112930515 @default.
• W2021156512 hasConceptScore W2021156512C126322002 @default.
• W2021156512 hasConceptScore W2021156512C127413603 @default.
• W2021156512 hasConceptScore W2021156512C160735492 @default.
• W2021156512 hasConceptScore W2021156512C162324750 @default.
• W2021156512 hasConceptScore W2021156512C164705383 @default.
• W2021156512 hasConceptScore W2021156512C17744445 @default.
• W2021156512 hasConceptScore W2021156512C177713679 @default.
• W2021156512 hasConceptScore W2021156512C199539241 @default.
• W2021156512 hasConceptScore W2021156512C2776301958 @default.
• W2021156512 hasConceptScore W2021156512C2776738588 @default.
• W2021156512 hasConceptScore W2021156512C2777628954 @default.
• W2021156512 hasConceptScore W2021156512C2779161974 @default.
• W2021156512 hasConceptScore W2021156512C2779473830 @default.
• W2021156512 hasConceptScore W2021156512C2780645631 @default.
• W2021156512 hasConceptScore W2021156512C3019080777 @default.
• W2021156512 hasConceptScore W2021156512C50522688 @default.
• W2021156512 hasConceptScore W2021156512C71924100 @default.

• next